An Early Phase 1 interventional study of Metformin and pep2dia in PCOS, sponsored by Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-03-28.
Sponsored by Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing metformin in Overweight — 4 open to participants now, 6 under way, none of them phase 3. Metformin · Overweight.
Among the 14 studies testing metformin in Overweight, this one is the 6th largest by enrollment, is one of 2 that started in 2024, is one of 2 in phase 1, and was the 9th registered.
3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.
Browse Overweight studies →4 of the 14 studies testing metformin in Overweight are open now, in 3 countries. Recruiting first, the newest first:
Riphah International University · Sites in Pakistan
Healthy volunteers
Fudan University · Sites in China
Ages 60–75
Johns Hopkins University · Sites in United States
Ages 18+
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.
This study: 18 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 2 · Phase 4 4
First in 2004; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 78 across 3,142 interventional studies indexed under Overweight.
Median enrollment 90 across the 14 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 14 have an industry lead sponsor. The 10 most frequent:
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy has 1 study filed under Overweight — fewer than ten, so there is no comparison to draw.
3 of the studies testing metformin in Overweight that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07550816Beijing QL Biopharmaceutical Co.,LtdDrug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants | 2026-12-05 |
| NCT06273072Johns Hopkins UniversityMetformin IN Asthma for Overweight and Obese Individuals (MINA) | 2026-12-31 |
| NCT07654179Riphah International UniversityMetformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation | 2027-06-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing metformin in Overweight, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare the effects of Metformin versus Pep2dia as adjunct treatments to Letrozole on ovulation induction and pregnancy outcomes in overweight women with polycystic ovary syndrome (PCOS). The main questions it aims to answer are:
Does Metformin improve ovulation rates more effectively than Pep2dia when used alongside Letrozole? Does Pep2dia enhance pregnancy outcomes compared to Metformin in this patient population?
Participants will:
Receive either Metformin or Pep2dia in addition to Letrozole. Undergo regular monitoring for ovulation and pregnancy outcomes. Researchers will compare the Metformin group to the Pep2dia group to see if there is a significant difference in ovulation and pregnancy rates between the two treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Two of the following three criteria are required:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the Metformin arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) who are experiencing infertility will participate. These participants will receive Letrozole for ovulation induction in combination with Metformin. The study will monitor these women to assess the efficacy of this treatment regimen on inducing ovulation and improving pregnancy outcomes. Participants will be closely observed for any side effects and their progress will be regularly evaluated to determine the effectiveness of Metformin as an adjunct therapy to Letrozole in this specific patient population.
Drug: Metformin
In the Pep2dia arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) who are experiencing infertility will participate. These participants will receive Letrozole for ovulation induction in combination with Pep2dia. The study will monitor these women to assess the efficacy of this treatment regimen on inducing ovulation and improving pregnancy outcomes. Participants will be closely observed for any side effects, and their progress will be regularly evaluated to determine the effectiveness of Pep2dia as an adjunct therapy to Letrozole in this specific patient population.
Drug: pep2dia
In the Metformin arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) and infertility will receive a combination treatment of Letrozole and Metformin. Letrozole, aimed at inducing ovulation, will be administered according to a specified dosage regimen, alongside Metformin, an insulin-sensitizing agent used to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and final evaluation of ovulation rates and pregnancy outcomes at the study's end. This arm seeks to determine the efficacy of Metformin as an adjunct to Letrozole in improving ovulation induction and pregnancy rates among overweight women with PCOS.
In the Pep2dia arm of this study, 50 overweight women diagnosed with polycystic ovary syndrome (PCOS) and experiencing infertility will receive a combination treatment of Letrozole and Pep2dia. Letrozole, utilized to induce ovulation, will be administered according to a specified dosage regimen, along with Pep2dia, a peptide-based therapy tailored to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and a final evaluation of ovulation rates and pregnancy outcomes at the conclusion of the study period. This arm seeks to ascertain the effectiveness of Pep2dia as an adjunct to Letrozole in enhancing ovulation induction and pregnancy rates among overweight women with PCOS.
Pregnancy rate:
detected by positive pregnancy test in serum (Chemical pregnancy) or presence of intrauterine gestational sac (Clinical pregnancy)
Time frame: 6 months
Ovulation rate:
detected by folliculometry and midluteal progesterone in serum (higher than 3 ng/mL)
Time frame: 6 months
Menstrual cycle regulation
Detection of regulation of the menstrual cycle that is not regular in patients with PCOS assessed as cycle length 21-35 days.
Time frame: 6 months
Side effects of both agents
Monitoring and recording of any adverse effects experienced by participants during the study period
Time frame: Throughout the study time (up to 1 year).
Ongoing pregnancy rate after the first trimester
Assessment of the proportion of pregnancies that progress beyond the first trimester
Time frame: first 13 weeks in pregnancy.
Plan to share: No — In accordance with the decision not to share individual participant data (IPD), strict measures will ensure confidentiality. Data collection will maintain anonymity, with unique identifiers replacing personal details. All data, from demographics to outcomes, will be securely stored in encrypted databases accessible only to authorized personnel. Individual participant data won't be shared externally; aggregate data may be shared while protecting privacy. Participants will be fully informed, addressing any concerns on data privacy during consent and throughout. The study protocol will undergo ethical review, ensuring compliance with confidentiality standards. Regular audits will monitor compliance with data security, promptly addressing breaches. These measures uphold participant confidentiality while investigating Metformin and Pep2dia effects on overweight women with PCOS undergoing Letrozole-induced ovulation.
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Mar 2025, 7 months.
Of 234 phase 1 interventional studies under Overweight, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy